10times
11 May 2021Ended

Exosome Manufacture Based on the iCELLis Bioreactor Platform

AboutSpeakersExhibitorsReviewsPhotos

Estimated Turnout

upto 100
Delegates
Based on previous editions

Editions

May 2021

Frequency

Not Available
Claim event to edit details

VivaZome Therapeutics is a privately-held Melbourne-based biotech company developing exosome therapeutics. Exosome manufacture involves separation .. Read more and concentration of exosomes from cell culture supernatant. Analysis of cell culture supernatant samples confirmed that exosome production was equivalent or better than that achieved in cells grown in tissue culture flasks. The iCELLis Nano bioreactor platform proved to be a flexible and efficient technology for culture of our adherent cells and suitable for generating substrate for exosome manufacture. David is experienced in the GMP manufacture of cellular based therapeutics and was Head of Experimental Cell Therapy at the Peter MacCallum Cancer Centre from 1999 until 2005. David is currently Chief Executive Officer of VivaZome Therapeutics, a Melbourne-based company developing exosome therapeutics. Exosomes are extracellular vesicles (EVs) secreted by most eukaryotic cells.

  • Share your Experience
  • Organizer
Logo Follow Company

BIOPHARMA ASIA MAGAZINE

South Korea74 Total Events / 11 Upcoming Events

More Events From The Organizer

You have no contacts. Please add contacts from below or share on social media

Send to all
No Results